Tanshinone IIA improves diabetes mellitus via the NF-κB-induced AMPK signal pathway

Abstract

Diabetes mellitus (DM) is a systemic metabolic disease. Tanshinone IIA (Tan-IIA) presents potential benefits for DM. The purpose of this study was to investigate the efficacy of Tan-IIA in type 2 DM rats and explore its potential mechanism in renal cells. A type 2 DM rat model was established and administered with Tan-IIA or PBS. It was demonstrated that Tan-IIA treatment significantly reduced levels of total cholesterol, non-esterified fatty acids, total triglyceride and low-density lipoprotein cholesterol in experimental DM rats compared with the control group. The results indicated that Tan-IIA treatment significantly decreased levels of interleukin (IL)-8, tumor necrosis factor-α, C-reactive protein and IL-6. It was identified that Tan-IIA treatment significantly decreased nuclear factor-κB levels and significantly elevated 5’ adenosine monophosphate-activated protein kinase levels. Western blot analysis indicated that Tan-IIA elevated immunocyte precipitation in renal cells. Furthermore, Tan-IIA treatment improved lipid metabolism, glucose metabolism, insulin resistance and body weight of type 2 DM rats. In conclusion, Tan-IIA administration may inhibit inflammatory cytokines and alleviate type 2 DM symptoms in experimental rats.